Gene · 5223
PGAM1: phosphoglycerate mutase 1
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. PGAM1: phosphoglycerate mutase 1. Genes, record 5223. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/5223
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P18669 | Phosphoglycerate mutase 1 | 254 | 33 | Ensembl, GeneID, HGNC |
Source UniProt
Patents79
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| WO 2026022479 A1 | 2026-01-29 | 1 | P18669 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 57850 | P18669 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 39423 | P18669 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 8870 | P18669 | Espacenet |
| EP 4640238 A1 | 2025-10-29 | 1 | P18669 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 9095 | P18669 | Espacenet |
| US 12441764 B2 | 2025-10-14 | 2 | P18669 | Espacenet |
| JP 2025517969 A | 2025-06-12 | 9095 | P18669 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 8870 | P18669 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 39423 | P18669 | Espacenet |
1 to 10 of 79
See all 79 patentsDrugs0
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
None in this release.
Trials0
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
None in this release.
NIH grants918
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | PGAM1 papers | Newest fiscal year |
|---|---|---|---|
| P30CA016672 | Cancer Center Support Grant | 9 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 6 | 2025 |
| R01CA140515 | Signaling importance of ‘functionless’ lyso-PAF, an inactive form of platelet activating factor, in melanoma with mutant Nras | 5 | 2025 |
| P30CA014195 | Cancer Center Support Grant (CCSG) | 4 | 2025 |
| P01CA120964 | Molecular Pathogenesis of the Hamartoma Syndromes | 3 | 2025 |
| P30CA006973 | Regional Oncology Research Center | 3 | 2025 |
| P30CA016042 | Cancer Center Support Grant | 3 | 2025 |
| P30CA016087 | Cancer Center Support Grant | 3 | 2025 |
| P30CA138292 | Winship Cancer Institute Cancer Center Support Grant | 3 | 2025 |
| R35CA220449 | Human metabolic variation as a window into cancer initiation and progression | 3 | 2025 |
1 to 10 of 918Source NIH's project files
See all 918 nih grantsPapers1,506
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| The impact of low carbohydrate diet on the plasma proteomic profile of individuals with obesity. | Front Nutr | 2026 | 42780918 | PubTator, text mining | PubMed |
| KDM6B inhibition modulates monocyte activation and alleviates IMQ-induced psoriasis-like skin inflammation. | Cell Commun Signal | 2026 | 42732058 | PubTator, text mining | PubMed |
| Targeting PGAM1 Y119 phosphorylation resensitizes non-small-cell lung cancer to cisplatin therapy by promoting oxidative stress and DNA damage. | J Biol Chem | 2026 | 42680101 | PubTator, text mining | PubMed |
| The function of phosphoglycerate mutase 1 (PGAM1) and its role in diseases. | Front Mol Biosci | 2026 | 42676892 | PubTator, text mining | PubMed |
| PGAM1 rheostat in glycolysis and autophagy. | Nat Cell Biol | 2026 | 42567989 | PubTator, text mining | PubMed |
| The glycolytic enzyme PGAM1 functions as a metabolic-autophagy checkpoint to coordinate growth and stress tolerance. | Nat Cell Biol | 2026 | 42527668 | PubTator, text mining | PubMed |
| N4-acetylcytidine modification bridges metabolic reprogramming and immune evasion in cancer: mechanisms and therapeutic implications. | Front Immunol | 2026 | 42445196 | PubTator, text mining | PubMed |
| USP20-mediated PGAM1 stabilization promotes glycolysis and confers osimertinib resistance in non-small cell lung carcinoma. | Oncogene | 2026 | 42420587 | PubTator, text mining | PubMed |
| Correction: LncRNA SPINT1-AS1 enhances the Warburg effect and promotes the progression of osteosarcoma via the miR-135b-5p/PGAM1 axis. | Cancer Cell Int | 2026 | 42316270 | PubTator, text mining | PubMed |
| The Warburg effect provides attributes that facilitate tumor-cell resistance. | Histol Histopathol | 2026 | 42311140 | PubTator, text mining | PubMed |
1 to 10 of 1,506
See all 1,506 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/5223
GET https://conductscience.org/api/genes/v1/5223/patents?page=2